<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50271">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902329</url>
  </required_header>
  <id_info>
    <org_study_id>SGN33A-001</org_study_id>
    <nct_id>NCT01902329</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-CD33A in AML Patients</brief_title>
  <official_title>A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety profile of SGN-CD33A administered as a single agent. The
      main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest
      dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute
      myeloid leukemia (AML).  The MTD will be determined by observing the dose-limiting
      toxicities (the side effects that prevent further increases in dose) of SGN-CD33A.  In
      addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-CD33A and metabolites</measure>
    <time_frame>Through 3 weeks after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete remission</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>SGN-CD33A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-CD33A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-CD33A</intervention_name>
    <description>Given intravenously every 3 weeks</description>
    <arm_group_label>SGN-CD33A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia, positive for CD33

          -  Eastern Cooperative Onocology Group status of 0 or 1

          -  Adequate baseline renal and hepatic function

          -  Central venous access

          -  Either achieved complete remission (greater than 12 weeks in duration) with initial
             induction/consolidation and have experienced relapse of disease or declined treatment
             with high-dose induction/consolidation

          -  Bone marrow blasts greater than or equal to 5% for relapsed patients, or greater than
             or equal to 20% for untreated patients

        Exclusion Criteria:

          -  Inadequate lung function

          -  Prior stem cell transplant

          -  High-dose chemotherapy within 4 weeks of study drug

          -  Antileukemia treatment within 14 days of study drug (other than hydroxyurea or
             6-mercaptopurine)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Blackman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Lowe</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinley Hurst</last_name>
      <phone>205-975-9481</phone>
      <email>mkhurst@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Harry Erba, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pennie Hien Lam</last_name>
      <phone>626-256-4673</phone>
      <email>hilam@coh.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Mimo</last_name>
      <phone>813-745-7362</phone>
      <email>Debra.Mimo@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Lancet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Loiselle</last_name>
      <phone>617-726-2261</phone>
      <email>CMLOISELLE@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Amir Fathi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein</last_name>
      <phone>212-639-3314</phone>
      <email>steine@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Eytan Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Fincher</last_name>
      <phone>216-445-3795</phone>
      <email>finchec@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Anjali Advani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daryn Flentje</last_name>
      <phone>801-213-4230</phone>
      <email>Daryn.Flentje@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Tibor Kovacsovics, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaysey Orlowski</last_name>
      <phone>206-667-1997</phone>
      <email>korlowsk@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Roland Walter, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>CD33 Antigen</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
